Document is current
Any future updates will be listed below
-
Authors
Karikari, Thomas K. https://orcid.org/0000-0003-1422-4358
Ashton, Nicholas J. https://orcid.org/0000-0002-3579-8804
Brinkmalm, Gunnar
Brum, Wagner S.
Benedet, Andréa L.
Montoliu-Gaya, Laia https://orcid.org/0000-0001-7684-6318
Lantero-Rodriguez, Juan https://orcid.org/0000-0002-7426-678X
Pascoal, Tharick Ali https://orcid.org/0000-0001-9057-8014
Suárez-Calvet, Marc https://orcid.org/0000-0002-2993-569X
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
- License Information
-
More Information
Article History
Accepted: 21 April 2022
First Online: 18 May 2022
Competing interests
: H.Z. has served on scientific advisory boards for CogRx, Denali, Pinteon Therapeutics, Roche Diagnostics, Samumed, Siemens Healthineers and Wave, and has given lectures in symposia sponsored by Alzecure, Biogen and Fujirebio. H.Z. is also a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant, on advisory boards, or on data monitoring committees for Abcam, Axon, Biogen, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). M.S.-C. has served as a consultant and on advisory boards for Roche Diagnostics International Ltd and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U and Roche Farma, S.A. The other authors report no competing interests.
